Severe insomnia is associated with metabolic syndrome in women over 50 years with major depression treated in psychiatry settings: a METADAP report

J Affect Disord. 2020 Mar 1:264:513-518. doi: 10.1016/j.jad.2019.11.084. Epub 2019 Nov 13.

Abstract

Introduction: Major depression is associated with metabolic syndrome and cardiovascular risk. We have previously shown that severe insomnia, a core symptom of major depression episode (MDE), is associated with hypertriglyceridemia, a component of metabolic syndrome, in women but not in men with major depression. Since insomnia is related to cardiovascular morbidity in the general population and major depression also, our objective was to assess the link between insomnia and metabolic syndrome, a marker syndrome of cardiovascular risk, during MDE, in women and in men.

Methods: In 624 patients with a current MDE cohort, both insomnia and metabolic syndrome were assessed in women and men. Insomnia was rated from 0 to 6 based on the HDRS corresponding items, severe insomnia being defined by a total insomnia score ≥4.

Results: severe insomnia was associated with metabolic syndrome in women but not in men. In multivariate logistic regressions, these results in women were independent from age, educational level, major depressive disorder duration and current smoking. These results were only significant in women aged ≥50 years, a cut-off age for menopausal status but not in women under 50 years.

Conclusion: Women aged ≥50 years with a severe insomnia during MDE have an increased risk of metabolic syndrome. Severe insomnia may be a clinical marker of metabolic risk in this population. They should be particularly monitored for metabolic syndrome and may benefit from sleep recommendations and cardiovascular prevention.

Keywords: Cardiovascular risk; Insomnia; MDD; MDE; Metabolic syndrome; Severe insomnia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azo Compounds
  • Depression
  • Depressive Disorder, Major* / epidemiology
  • Female
  • Humans
  • Male
  • Metabolic Syndrome* / complications
  • Metabolic Syndrome* / epidemiology
  • Middle Aged
  • Psychiatry*
  • Sleep Initiation and Maintenance Disorders* / epidemiology

Substances

  • Azo Compounds
  • 2-(4-methyl-2-thiazolylazo)-5-diethylaminophenol